ELENCO DELLE PRIME 15 AZIENDE FRANCESI NEL SETTORE BIOTECH REGIONE ILE DE FRANCE 1_ LFB –Sede centrale Laboratoire Français du Fractionnement et des Biotechnologies 3 avenue des Tropiques - BP 305 – Les Ulis 91958 Courtaboeuf Cedex – France Telefono : 0033 1 69 82 70 10 0033 1 69 07 19 03 communication@lfb.fr Sito Web : www.lfb.fr Presenza in Francia LFB Biomédicaments (Lille) Sito produttivo a Les Ulis (91000) Presenza all’estero Filiale in Brasile, Germania e Regno Unito
Dati principali 2008 Responsabili Direttore : Direttore Affari Generali Presentazione e/o prodotti
Leader in France in the field of plasma-derived medicinal products, 6th player wordwide, LFB Group is also one of the leading European companies for the development of monoclonal antibodies and new-generation proteins based on biotechnologies.
LFB is dedicated to developing, manufacturing and marketing medicinal products for serious , and often rare diseases . R&D is key to tehe strategy of LFB Group. With a 2008 budget amounting to nearly 20% of the turnover, research projects concern both a number of developments in the field of plasma proteins,and the marketing of products based on biotechnologies, in essential therapeutic areas such as immunology, hemostasis, intensive care and oncology.
44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
2_ ETHYPHARM S.A–Sede centrale 194 bureaux de la colline, Bat D 92 213 Saint-Cloud France Telefono : 0033 1 41 12 17 20 0033 1 41 12 17 30 : contact@ethypharm.com Sito web : www.ethypharm.com Presenza in Francia : + 1 laboratorio a Chateauneuf en Thymerais - (28170) + 2 siti produttivi (Houdan –Le Grand Quevilly)- (76120) Responsabili Direttori Generali: Dati principali 2008 Presenza all’estero
Ethypharm North America -200 boul. Armand-Frappier, Laval, Québec, (Canada) H7V 4A6 touam.hafid@ethypharmusa.com Ethypharm USA Inc. -1500 Market Street, 12th Floor, East Tower - Philadelphia, PA, 19102, USA touam.hafid@ethypharmusa.com Ethypharm China - C-D, 11 Floor, 9 Joy Tower, No.9, Zhen Ning Road, 200051 -Shanghai, China - hao.xiaofan@ethypharm.com.cn Ethypharm India - Fortune 200 C1, 2nd, Bandra Kurla Complex, Bandra East, Mumbai – 400 051 - vksingh@ethypharmindia.com Ethypharm JapanShiodome Shibarikyu Bldg. 21F, 1-2-3 Kaigan, Minato-ku, Tokyo 105-0022, Japan - ukai_keiko@ethypharm.co.jp Prodotti Tramadol, Oxycodone, Ketoprofen Omeprazole, Morphine Sulfate, which totalizes more than 80% market shares in France for immediate or delayed release oral forms. Buprenorphine - The Company is also dedicated to the development of modified release oral forms of products destined for treatment of central nervous system diseases for the treatment of opiate addiction, and Mirtazapine for depression. Ethypharm has also concentrated upon formulations and key developments in the cardiovascular field. Over 10 products are presently marketed on a world-wide scale, such as Diltiazem, ISMN or Fenofibrate. Ethypharm recently developed Esomeprazole, a product that logically comes just after the success of the launch of its Omeprazole.
44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
3_ HYBRIGENICS- Sede 3-5 impasse Reille 75014 Paris France Telefono : 0033 1 58 10 38 00 0033 11 58 10 38 49 contact@hybrigenics.com Sito web : www.hybrigenics.com Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund - (milioni di €)
Totale sovvenzioni ricevute (milioni di €)
Responsabili Direttore : Presenza all’estero USA/Canada - Bioteam Boston +1 617 583 1350 Japon - CTC Laboratory System +81 (0)3 3419 9347 Presentazione e/o prodotti Hybrigenics was founded in 1997 as a spin-off of Pasteur Institute to develop and industrialize a high throughput platform to detect and identify protein interactions using the two-hybrid technology in yeast (Yeast Two-Hybrid, Y2H). Hybrigenics is a biotechnology and pharmaceutical company focusing its internal R&D programs on innovative
target and therapeutics against cancer and commercializing its high throughput technology and bioinformatics
platforms to identify, validate and inhibit protein interactions.
Hybrigenics’ most advanced development program is based on inecalcitol, a vitamin D analogue, for prostate
cancer in combination with current reference treatments, for improved efficacy and better tolerance.
Hybrigenics’ research program explores the role of Ubiquitin-Specific Proteases (USPs) in the degradation of
onco-proteins, and the use of proprietary USP inhibitors against various cancer types.
Hybrigenics offers to researchers from all life sciences an access to its ISO 9001-certified Yeast-Two Hybrid
(Y2H) high throughput screening platform, to its sophisticated bioinformatics set of tools and extensive
database, and to its chemical library and high throughput small molecule screening platform, as fee-for-service
Hybrigenics is organized in two operational units: Hybrigenics Pharma for the internal R&D programs and
Hybrigenics Services for the commercial business, coordinated with economies of scale by a common corporate,
44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
financial and administrative management. The core link among all Hybrigenics activities is trust in science for
life. _ 4 CEREP- Sede principale 155 Boulevard Haussmann 75008 Paris France Telefono : 0033 1 45 64 44 60 0033 1 45 64 44 64 sales@cerep.fr www.cerep.fr Presenza in Francia : + 1 stabilimento a Poitiers (86000) Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund - (milioni di €)
Totale sovvenzioni ricevute (milioni di €)
Responsabili Direttore Thierry Direttore scientifico Olivier Presenza all’estero Redmond, WA (USA), Sales office in Tokyo (Japan)
Presentazione
Cerep offers preclinical drug discovery services for in vitro pharmacology, in vitro ADME-Tox & in vivo pharmacokinetics, and provides solutions allowing faster and cost-effective drug discovery by identifying at early stages the most promising drug candidates as wel as eliminating those compounds likely to fail in development. Cerep has developed unique know-how based on technologies of in vitro screening and of profiling using its proprietary database BioPrint®, which allows the modeling of clinical effects of drug candidates from their molecular properties. The strength of our services also originates from our in-house production of biological material or from established partnerships with renowned reagents providers (such as PerkinElmer). Cerep’s technologies benefit to more than 460 pharmaceutical and biotechnological companies worldwide including most of the top pharmaceutical firms. Cerep’s next objective is to open satellite laboratories, closer to where compounds are synthesized and drug candidates optimized, thus further decreasing turnaround time for data Bureau de Paris
44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
generation and delivery to discovery teams. The success of this endeavour can only be achieved through the provision of consistent high quality data – reason for Cerep’s permanence – wherever the screening is performed. 5 _ BIOALLIANCE PHARMA 49 bis Bd du Général Martial Val 75015 Paris Telefono : 0033 1 45 58 76 00 0033 1 45 58 08 81 bioalliance@bioalliancepharma.com Sito Web : www.bioalliancepharma.com Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund -(milioni di €) 104 Totale sovvenzioni ricevute (milioni di €) 1,5
Responsabili Presidente : Direttore generale
Presentazione e/o prodotti
Development of novel approaches for treating HIV and cancer.
44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
6 _ CELLECTIS 102 avenue Gaston Roussel 93230 Romainville Telefono : 0033 1 41 83 99 00 0033 1 41 83 99 03 mail@cellectis.com Sito Web : www.cellectis.com Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund -(milioni di €) 42,2 Totale sovvenzioni ricevute (milioni di €) Responsabili Direttore :
Prodotti
Cellectis Sa is a word leader in genome engineering. The company specializes in the development and production of meganucleases (DNA scissors) for in vivo genome surgery. Cellectis products are programmed to induce unique, site-directed, double-strand DNAbreaks in a living cell and can be used for a wide range of therapeutic and biotechnological applications. Bureau de Paris
44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
7 _ EXONHIT THERAPEUTICS HYBRIGENICS 65 boulevard Masséna 75013 Paris Telefono : 0033 1 53 94 77 00 0033 1 58 05 47 19 pleaseforward@exonhit.com Sito Web : www.exonhit.com
Presenza in Francia : Dati principali 2008
Totale Equity fund dalla data di creazione –- (milioni di €)
Totale sovvenzioni ricevute (milioni di €)
Responsabili Direttore amministrativo: Direttore R&D: Presenza all’estero ExonHit Therapeutics Inc. Avenel Business Park 217 Perry Parkway Gaithersburg, MD 20877 Tel: +1 (240) 683-7070 - Fax: +1 (240) 683-7060
Presentazione e/o prodotti
Drug discovey and diagnostics; a leader in the field of alternative RNA splicing. A strong commercial position in the microarray disgnostics and drug market.
44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
REGIONE NORD OUEST 8_ VIVALIS 6 rue Alain Bombard 44800 Saint Herblain Cedex Nantes - France Telefono 0033 2 38 07 37 10 0033 2 28 07 37 11 info@vivalis.com Sito web : www.vivalis.com
Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund - (milioni di €)
Totale sovvenzioni ricevute (milioni di €)
Responsabili Presidente : Franck Grimaud Direttore R&D Majid Methali Presentazione e/o prodotti
Vivalis is a listed biopharmaceutical company that provides innovative cell-based solutions for the industrial manufacture of viral vaccines and therapeutic proteins. It is also developing vaccines and drugs for preventing and treating viral diseases.
44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
REGIONE NORD -ESTE 9_ GENFIT Parc Eurasanté 885 avenue Eugène Avinée 59120 Loos Telefono : 0033 3 20 16 40 00 0033 3 20 16 40 06 contact@genfit.com Sito web : www.genfit.com Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund - (milioni di €)
Totale sovvenzioni ricevute (milioni di €)
Responsabili Direttore Generale : Presenza all’estero
Genfit Corp. 245 First Street, 18 th floor – Cambridge MA 02142 (USA) – Phone + 1 (617) 444 84 16 – Fax +1 (617) 444 8405 Presentazione e/o prodotti
Genfit’s research efforts are focused on the discovey and development of new treatments in the growing therapeutis areas of cardiometabolic and neurodegenerative disosrders, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity,and Alzeimer’s.
44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
10_ TRANSGENE Boulevard Gonthier d’Andernach Parc Innovation –CS 801 67405Illkirch-Graffenstaden Cedex France Presenza in Francia :
Telefono : 0033 3 88 27 91 00 0033 3 88 22 58 07 communication@transgene.fr Sito web : www.transgene.fr Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund - (milioni di €)
Totale sovvenzioni ricevute (milioni di €)
Responsabili Direttore generale: Presenza all’estero Transgene Inc. 5510 Nicholson Lane Kensington, Maryland 20895-1078 – USA Prodotti
Vaccini terapeutici e prodotti di immunoterapie.
44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
REGIONE RHONE-ALPES 11_ FLAMEL TECHNOLOGIES 33 avenue du Dr. Georges Levy 69693 Venissieux Cedex France Presenza in Francia :
+1 stabilimento a Pessac (Francia) Telefono : 0033 4 72 78 34 34 0033 4 72 78 34 35 info@flamel.com Sito web : www.flamel.com Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund - (milioni di €)
Totale sovvenzioni ricevute (milioni di €)
Responsabili Direttore : Direttore produzione: Presenza all’estero USA, Nigel McWilliam (Director, Business Development) - E-mail: mcwilliam@flamel.com Prodotti Medusa®, a self-assembled poly-aminoacid nanoparticle system, is a versatile protein carrier for the development of novel and second-generation long-acting native protein drugs. Medusa may also be applied other large molecules, such as monoclonal antibody fragments and peptides. The Medusa® platform has many advantages in that it enables the controlled delivery of fully-human, non-denatured proteins. We believe that this will lead to a second-generation of protein-based drugs offering greater effectiveness and reduced toxicity and
44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
side-effects to patients. A microparticulate adaptation of Medusa has been developed that potentially can extend pharmacokinetics to two weeks or more, also without loss of bioactivity.
The Micropump® platform enables the controlled delivery of small molecule drugs that are best absorbed in the small intestine, a description that fits more than 70% of orally administered drugs. Unlike gastric-retention tablets, the Micropump® platform is well suited for applications geared towards pediatric and geriatric patients. That is because the Micropump® technology consists of the encapsulation of thousands of micro-particules, each measuring 200-500 micrometers in diameter. These microparticles can be delivered in caplets but they can also be delivered in suspensions or syrups. Because the active ingredients are entirely enclosed in each micro- particle, Micropump® offers an additional advantage of taste masking. 12_ GENOWAY 181 Avenue Jean Jaurès 69007 Lyon - France Telefono : 0033 4 37 65 41 00 info@genoway.com Sito web : www.genoway.com Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund - (milioni di €)
Totale sovvenzioni ricevute (milioni di €)
Responsabili Direttore : Alexandre Fraichard
Prodotti
GenOway is a service provider dedicated to the development of genetically modified mouse and rat models. GenOway’s technology platform comprises technologies classically used in transgenesis such a pronuclear microinjection, gene knock-out, knock-in and knock-down, together with conditional and inducible systems and several innovative approaches.
44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
REGIONE SUD-EST 13_ INNATE PHARMA - Sede 117, Avenue de Luminy – BP 30191 13009 Marseille - France Telefono : 0033 4 30 30 30 87 0033 4 30 30 30 00 business@innate-pharma.com Sito web : www.innate-pharma.com Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund - (milioni di €)
Totale sovvenzioni ricevute (milioni di €)
Responsabili Direttore : Hervé Braille François Presenza all’estero
Redmond, WA (USA), Sales office in Tokyo (Japan)
Prodotti Therapeutic area, oncology, inflammation and oncology infections.
Bureau de Paris
44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
14_ IPSOGEN - Sede 163 Avenue de Luminy 13009 Marseille 09 - France Telefono : 0033 4 91 29 30 90 0033 4 91 29 30 99 infos@ipsogen.com Sito web : www.ipsogen.com Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund - (milioni di €)
Totale sovvenzioni ricevute (milioni di €)
Responsabili Direttore : Vincent Fert Presenza all’estero
Ipsogen Inc. Stamford – Connecticut (USA) Prodotti
Leucemia and breast cancer products.
44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
15_ NICOX BP 313 06906 Sophia Antipolis Cedex France Telefono : 0033 4 97 24 53 00 0033 4 97 24 53 09 nicox@nicox.com Sito web : www.nicox.com Dati principali 2008
Totale investimenti dalla data di creazione –Equity fund - (milioni di €) Responsabili Direttore : Michele Garufi Presenza all’estero
Nicox Research Institute Srl (Italia) Nicox Inc. (Stati Uniti) Prodotti
NicOx' most advanced investigational drug, naproxcinod, has successfully completed a
clinical phase 3 program in patients with osteoarthritis of the knee and hip. Anti-
inflammatory agents currently used in the treatment of osteoarthritis (traditional NSAIDs
and COX-2 inhibitors) have long been associated with a range of side effects, including
gastrointestinal problems. Furthermore, clinical findings continue to cast significant doubt
on their cardiovascular safety, including their association with increased blood pressure.
44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
Naproxcinod is a unique nitric oxide-donating anti-inflammatory compound and the first-
in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide Donator) in late-phase
development. NicOx aims to demonstrate that naproxcinod is an anti-inflammatory agent
with no detrimental effect on blood pressure and good gastrointestinal tolerability and
NicOx has completed a clinical phase 3 program for naproxcinod in patients with OA of
the knee (the 301 and 302 studies) and hip (the 303 study), with all three studies
achieving highly statistically significant results on all three co-primary efficacy endpoints.
NicOx submitted a New Drug Application (NDA) for naproxcinod to the US Food and Drug
Administration (FDA) in September 2009. NicOx received a communication in November
2009 from the FDA stating that the NDA was accepted for filing. Based on the
Prescription Drug User Fee Act (PDUFA), the FDA will complete its review 10 months
after submission and has set an action date of July 24, 2010. The submission of a
Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) is
44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it
F O R T B I L D U N G Die Multiple Sklerose (MS) kann zu erheblichen Funktionsdefiziten und Behinderungen führen. Eine umfassende stationäre Rehabilitationsbehandlung kann die Auswirkungen der Funktionsstörungen minimieren. Der Klinikleiter und Chefarzt Dr. Claude Vaney von der Berner Klinik Montana blickt auf eine 25-jährige Erfahrung im Bereich Rehabilitation bei MS zurüc
Anaphylaxis is highly likely when any one of the following 3 criteria are fulfilled 1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips / tongue / uvula) and at least one of the following: a. Respiratory compromise (e.g., dyspnea, wheeze / bronchospasm, stridor, reduced PEF,
ELENCO DELLE PRIME 15 AZIENDE FRANCESI NEL 
financial and administrative management. The core link among all Hybrigenics activities is trust in science for
life. 
generation and delivery to discovery teams. The success of this endeavour can only be 
side-effects to patients. A microparticulate adaptation of Medusa has been developed that potentially can extend pharmacokinetics to two weeks or more, also without loss of bioactivity.
The Micropump® platform enables the controlled delivery of small molecule drugs that are best absorbed in the 
Naproxcinod is a unique nitric oxide-donating anti-inflammatory compound and the first-
in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide Donator) in late-phase
development. NicOx aims to demonstrate that naproxcinod is an anti-inflammatory agent
with no detrimental effect on blood pressure and good gastrointestinal tolerability and
NicOx has completed a clinical phase 3 program for naproxcinod in patients with OA of
the knee (the 301 and 302 studies) and hip (the 303 study), with all three studies
achieving highly statistically significant results on all three co-primary efficacy endpoints.
NicOx submitted a New Drug Application (NDA) for naproxcinod to the US Food and Drug
Administration (FDA) in September 2009. NicOx received a communication in November
2009 from the FDA stating that the NDA was accepted for filing. Based on the
Prescription Drug User Fee Act (PDUFA), the FDA will complete its review 10 months
after submission and has set an action date of July 24, 2010. The submission of a
Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) is
44, rue Paul Valéry - 75116 Paris Tel : +33 1 53 75 70 00 E.mail : parigi@ice.it